Tissue distribution of berberine and its metabolites after oral administration in rats - PubMed (original) (raw)
. 2013 Oct 31;8(10):e77969.
doi: 10.1371/journal.pone.0077969. eCollection 2013.
Jing-Yi Ma, Ru Feng, Chao Ma, Wen-Jing Chen, Yu-Peng Sun, Jie Fu, Min Huang, Chi-Yu He, Jia-Wen Shou, Wen-Yi He, Yan Wang, Jian-Dong Jiang
Affiliations
- PMID: 24205048
- PMCID: PMC3815028
- DOI: 10.1371/journal.pone.0077969
Tissue distribution of berberine and its metabolites after oral administration in rats
Xiang-Shan Tan et al. PLoS One. 2013.
Abstract
Berberine (BBR) has been confirmed to have multiple bioactivities in clinic, such as cholesterol-lowering, anti-diabetes, cardiovascular protection and anti- inflammation. However, BBR's plasma level is very low; it cannot explain its pharmacological effects in patients. We consider that the in vivo distribution of BBR as well as of its bioactive metabolites might provide part of the explanation for this question. In this study, liquid chromatography coupled to ion trap time-of-flight mass spectrometry (LC/MS(n)-IT-TOF) as well as liquid chromatography that coupled with tandem mass spectrometry (LC-MS/MS) was used for the study of tissue distribution and pharmacokinetics of BBR in rats after oral administration (200 mg/kg). The results indicated that BBR was quickly distributed in the liver, kidneys, muscle, lungs, brain, heart, pancreas and fat in a descending order of its amount. The pharmacokinetic profile indicated that BBR's level in most of studied tissues was higher (or much higher) than that in plasma 4 h after administration. BBR remained relatively stable in the tissues like liver, heart, brain, muscle, pancreas etc. Organ distribution of BBR's metabolites was also investigated paralleled with that of BBR. Thalifendine (M1), berberrubine (M2) and jatrorrhizine (M4), which the metabolites with moderate bioactivity, were easily detected in organs like the liver and kidney. For instance, M1, M2 and M4 were the major metabolites in the liver, among which the percentage of M2 was up to 65.1%; the level of AUC (0-t) (area under the concentration-time curve) for BBR or the metabolites in the liver was 10-fold or 30-fold higher than that in plasma, respectively. In summary, the organ concentration of BBR (as well as its bioactive metabolites) was higher than its concentration in the blood after oral administration. It might explain BBR's pharmacological effects on human diseases in clinic.
Conflict of interest statement
Competing Interests: The authors have declared that no competing interests exist.
Figures
Figure 1. BBR mass spectrographic behavior and its metabolism in tissues.
1A Structure of BBR 1B Mass spectrographic behavior of BBR 1C Representative EIC chromatogram of BBR and its metabolites in liver (8 h) in rat.
Figure 2. Tissue distribution of BBR.
2A Plasma concentration-time profile of BBR after oral administration of 200 mg/kg in 48 h (n = 6) 2B Profiles of BBR in liver distribution in SD rats after oral administration of 200 mg/kg (n = 6) 2C Profiles of BBR in kidney distribution in SD rats after oral administration of 200 mg/kg (n = 6) 2D Profiles of BBR in muscle distribution in SD rats after oral administration of 200 mg/kg (n = 6) 2E Profiles of BBR in lung distribution in SD rats after oral administration of 200 mg/kg (n = 6) 2F Profiles of BBR in brain distribution in SD rats after oral administration of 200 mg/kg (n = 6) 2G Profiles of BBR in heart distribution in SD rats after oral administration of 200 mg/kg (n = 6) 2H Profiles of BBR in pancreas distribution in SD rats after oral administration of 200 mg/kg (n = 6) 2I Profiles of BBR in fat distribution in SD rats after oral administration of 200 mg/kg (n = 6).
Figure 3. Tissue distribution of metabolites of BBR.
3A Profiles of BBR and its metabolites in liver distribution in SD rats after oral administration of 200/kg (n = 6) 3B Profiles of BBR and its metabolites in kidney distribution in SD rats after oral administration of 200 mg/kg (n = 6) 3C Profiles of BBR and its metabolites in lung distribution in SD rats after oral administration of 200 (n = 6) 3D Profiles of BBR and its metabolites in muscle distribution in SD rats after oral administration of 200 mg/kg (n = 6) 3E Profiles of BBR and its metabolites in pancreas distribution in SD rats after oral administration of 200 mg/kg (n = 6) 3F Profiles of BBR and its metabolites in heart distribution in SD rats after oral administration of 200 mg/kg (n = 6).
Similar articles
- Bioactivities of berberine metabolites after transformation through CYP450 isoenzymes.
Li Y, Ren G, Wang YX, Kong WJ, Yang P, Wang YM, Li YH, Yi H, Li ZR, Song DQ, Jiang JD. Li Y, et al. J Transl Med. 2011 May 15;9:62. doi: 10.1186/1479-5876-9-62. J Transl Med. 2011. PMID: 21569619 Free PMC article. - Excretion of berberine and its metabolites in oral administration in rats.
Ma JY, Feng R, Tan XS, Ma C, Shou JW, Fu J, Huang M, He CY, Chen SN, Zhao ZX, He WY, Wang Y, Jiang JD. Ma JY, et al. J Pharm Sci. 2013 Nov;102(11):4181-92. doi: 10.1002/jps.23718. Epub 2013 Sep 4. J Pharm Sci. 2013. PMID: 24006193 - Pharmacokinetic studies of novel berberine derivatives with ultra-performance liquid chromatography-tandem mass spectrometry.
Wang W, Shen Q, Liang H, Hua C, Liu Y, Li F, Li Q. Wang W, et al. J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Sep 15;1031:172-180. doi: 10.1016/j.jchromb.2016.07.038. Epub 2016 Jul 18. J Chromatogr B Analyt Technol Biomed Life Sci. 2016. PMID: 27494281 - [Effect of berberine in treating type 2 diabetes mellitus and complications and its relevant mechanisms].
Zhang Q, Li Y, Chen L. Zhang Q, et al. Zhongguo Zhong Yao Za Zhi. 2015 May;40(9):1660-5. Zhongguo Zhong Yao Za Zhi. 2015. PMID: 26323125 Review. Chinese. - Research progress on berberine with a special focus on its oral bioavailability.
Liu CS, Zheng YR, Zhang YF, Long XY. Liu CS, et al. Fitoterapia. 2016 Mar;109:274-82. doi: 10.1016/j.fitote.2016.02.001. Epub 2016 Feb 2. Fitoterapia. 2016. PMID: 26851175 Review.
Cited by
- Advances in the pharmacological mechanisms of berberine in the treatment of fibrosis.
Liu X, Liang Q, Wang Y, Xiong S, Yue R. Liu X, et al. Front Pharmacol. 2024 Sep 20;15:1455058. doi: 10.3389/fphar.2024.1455058. eCollection 2024. Front Pharmacol. 2024. PMID: 39372209 Free PMC article. Review. - In Silico Predicting the Presence of the S100B Motif in Edible Plants and Detecting Its Immunoreactive Materials: Perspectives for Functional Foods, Dietary Supplements and Phytotherapies.
Romano Spica V, Volpini V, Valeriani F, Carotenuto G, Arcieri M, Platania S, Castrignanò T, Clementi ME, Michetti F. Romano Spica V, et al. Int J Mol Sci. 2024 Sep 11;25(18):9813. doi: 10.3390/ijms25189813. Int J Mol Sci. 2024. PMID: 39337302 Free PMC article. - Natural Products and Derivatives Targeting Metabolic Reprogramming in Colorectal Cancer: A Comprehensive Review.
Wang M, Qu L, Du X, Song P, Ng JPL, Wong VKW, Law BYK, Fu X. Wang M, et al. Metabolites. 2024 Sep 9;14(9):490. doi: 10.3390/metabo14090490. Metabolites. 2024. PMID: 39330497 Free PMC article. Review. - Neuroprotective effect and preparation methods of berberine.
Sunhe YX, Zhang YH, Fu RJ, Xu DQ, Tang YP. Sunhe YX, et al. Front Pharmacol. 2024 Sep 6;15:1429050. doi: 10.3389/fphar.2024.1429050. eCollection 2024. Front Pharmacol. 2024. PMID: 39309003 Free PMC article. Review. - Systemic Pharmacotherapeutic Treatment of the ACTA1-MCM/FLExDUX4 Preclinical Mouse Model of FSHD.
Lu-Nguyen N, Snowden S, Popplewell L, Malerba A. Lu-Nguyen N, et al. Int J Mol Sci. 2024 Jun 26;25(13):6994. doi: 10.3390/ijms25136994. Int J Mol Sci. 2024. PMID: 39000102 Free PMC article.
References
- Zhang DF, Li AH, Xie J, Ji C (2010) In vitro antibacterial effect of berberine hydrochloride and enrofloxacin to fish pathogenic bacteria. Aquaculture Research 41: 1095–1100.
- Bahar M, Deng Y, Zhu XH, He SS, Pandharkar T, et al. (2011) Potent antiprotozoal activity of a novel semi-synthetic berberine derivative. Bioorganic & Medicinal Chemistry Letters 21: 2606–2610. - PubMed
- Kong W, Wei J, Abidi P, Lin M, Inaba S, et al. (2004) Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nature Medicine 10: 1344–1351. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
The project was supported by National Science and Technology Special Projects (2012ZX09301-002-001, 2012ZX09301-002006), and the financial support from the National Natural Science Foundation of China (No. 30873115and 81072611). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
LinkOut - more resources
Full Text Sources
Other Literature Sources